Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01856634
Other study ID # 242-12-232
Secondary ID
Status Completed
Phase Phase 1
First received May 15, 2013
Last updated January 27, 2018
Start date June 14, 2013
Est. completion date December 28, 2017

Study information

Verified date January 2018
Source Otsuka Pharmaceutical Development & Commercialization, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this trial is to determine the pediatric dose of delamanid that is equivalent to the adult dose already shown to be effective against multidrug-resistant tuberculosis.


Description:

This trial will investigate the pharmacokinetics (PK) and safety of delamanid administered for 10 days to pediatric patients aged birth to 17 years who are also on therapy with an optimized background regimen. The purpose of the trial is to determine which dose in pediatric MDR-TB patients will result in delamanid plasma exposure similar to efficacious plasma exposure in adult MDR-TB patients. This is an age de-escalation trial in four groups:

Group 1: 12 to 17 years (100 mg BID; n=6) Group 2: 6 to 11 years (50 mg BID; n=6) Group 3: 3 to 5 years (25 mg BID; n=12) Group 4: Birth to 2 years (Dose based on patient's body weight, n=12)

- Patients > 10 kg will receive 10 mg BID

- Patients > 8 kg and ≤ 10 kg will receive 5 mg BID

- Patient ≤ to 8 kg will receive 5 mg QD


Recruitment information / eligibility

Status Completed
Enrollment 37
Est. completion date December 28, 2017
Est. primary completion date December 10, 2017
Accepts healthy volunteers No
Gender All
Age group N/A to 17 Years
Eligibility Inclusion Criteria:

- Confirmed diagnosis of MDR-TB OR

- Presumptive diagnosis of MDR-TB including one of the following:

- Clinical specimen suggestive of TB

- Persistent cough lasting > 2 weeks

- Fever, weight loss, and failure to thrive

- Findings on recent chest radiograph (prior to Visit 1) consistent with TB AND

- Household contact of a person with known MDR-TB or a person who died while appropriately taking drugs for sensitive TB OR

- On first-line TB treatment but with no clinical improvement

- Negative urine pregnancy test for female patients who have reached menarche

- Written informed consent/assent

Exclusion Criteria:

- Laboratory evidence of active hepatitis B or C

- Children with body weight < 5.5 kg

- For patients with HIV co-infection, CD4 cell count = 1000/mm3 for children 1-5 years old, and = 1500/mm3 for children less than 1 year old

- History of allergy to metronidazole and any disease or condition in which metronidazole is required

- Use of amiodarone within 12 months or use of other predefined antiarrhythmic medications within 30 days prior to first dose of delamanid

- Serious concomitant conditions

- Preexisting cardiac conditions

- Abnormalities in Screening ECG (including AV block, BBB or hemi-block, QRS prolongation > 120 msec, or QTcF > 450 msec in both males and females)

- Concomitant condition such as renal impairment characterized by serum creatinine levels >1.5 mg/dL, hepatic impairment (ALT or AST > 3x ULN), or hyperbilirubinemia characterized by total bilirubin > 2x ULN

- Current diagnosis of severe malnutrition or kwashiorkor

- Positive urine drug screen (Groups 1 and 2 only)

- Rifampicin and/or moxifloxacin within 1 week prior to the first dose of delamanid and/or any prior or concurrent use of bedaquiline

- Lansky Play Performance Score < 50 (not applicable for children < 1 year old) or Karnofsky Score < 50

- Administered an IMP within 1 month prior to Visit 1

- Pregnant, breast-feeding, or planning to conceive or father a child within the timeframe described in the information consent form (Groups 1 and 2 only)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
100 mg Delamanid
100 mg Delamanid BID for 10 days
50 mg Delamanid
50 mg Delamanid BID for 10 days
25 mg Pediatric Formulation Delamanid
25 mg Pediatric Formulation Delamanid BID for 10 days
10 mg Delamanid Pediatric Formulation
Patients > 10 kg will receive DPF 10 mg BID for 10 days
5 mg Delamanid Pediatric Formulation
Patients > 8 kg and = 10 kg will receive DPF 5 mg BID for 10 days Patients = 8 kg will receive DPF 5 mg QD for 10 days
Optimized Background Regimen
Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country

Locations

Country Name City State
Philippines De La Salle Health Sciences Institute Dasmariñas Cavite
South Africa Brooklyn Chest Hospital Ysterplaat Cape Town

Sponsors (1)

Lead Sponsor Collaborator
Otsuka Pharmaceutical Development & Commercialization, Inc.

Countries where clinical trial is conducted

Philippines,  South Africa, 

Outcome

Type Measure Description Time frame Safety issue
Primary Plasma Concentrations Plasma concentrations (Cmax, tmax, AUC 0-24h, accumulation ratio, apparent terminal elimination half-life, apparent total clearance) of delamanid and its metabolites on Days 1, 2, 10, 11, 13 (Groups 1 and 2 only), 15, 18. Days 1, 2, 10, 11, 13 (Groups 1 and 2 only), 15, 18
Secondary Adverse Events Number of reported adverse events 40 Days
Secondary Safety Summary Summary statistics of subjects with clinically significant abnormal laboratory test results, vitals, ECGs 40 Days
Secondary Palatability of the Pediatric Formulation Palatability of the pediatric formulation will be assessed using an age-appropriate visual hedonic scale and clinical assessment for Groups 3 and 4 only. Days 1 and 10
See also
  Status Clinical Trial Phase
Completed NCT04176822 - Designing Animated Movie for Preoperative Period N/A
Completed NCT01981954 - A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO) Phase 3
Completed NCT02199626 - SECOND GENERATION COLON CAPSULE ENDOSCOPY (CCE-2) IN PEDIATRIC CROHN'S DISEASE (CD). Phase 4
Recruiting NCT04679792 - Postual Control in Pediatric Chiari I Malformation
Recruiting NCT06061159 - The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction Phase 4
Active, not recruiting NCT05453968 - Berotralstat Treatment in Children With Hereditary Angioedema Phase 3
Not yet recruiting NCT02182648 - Bispectral Index Guiding Etomidate Used in Children Aged 3 to 10 for Clinical Anesthesia Induction Phase 4
Active, not recruiting NCT04176640 - Quantifying Brain Injury on Computed Tomography in Hospitalized Children
Active, not recruiting NCT06146452 - Micronutrient Status in Pediatric Palliative Care
Completed NCT04041180 - Impact on the Length of Stay in Incentive Spirometry and Pain in the Decompensation of Sickle Cell Disease: .
Not yet recruiting NCT06165003 - Examination of Nurses' Use of Broselow Tape in Non-resuscitation Pediatric Emergency Department Practices N/A
Recruiting NCT02286297 - Pediatric Endotracheal Intubation During Resuscitation N/A
Unknown status NCT00613184 - Comparison of Nylon Flocked Swabs and Saline Aspirates for Detection Respiratory Viruses N/A
Recruiting NCT00265772 - Comparison of a Nutritional Anti-Inflammatory Treatment to Steroids for Pediatric Crohn's Disease - the Molecular Basis Phase 4
Completed NCT04106063 - A New Speech, Spatial, and Qualities of Hearing Scale Short-Form for Deaf Children
Not yet recruiting NCT06376643 - Augmented Reality to Support Cardiopulmonary Resuscitation N/A
Not yet recruiting NCT05511233 - ERAS Protocol in Newborns: CARES Study N/A
Not yet recruiting NCT04127968 - Efficacy and Safety of Vitamin A Treatment for Children With Sepsis N/A
Active, not recruiting NCT04472286 - Healthy Bones, Healthy Life: Habitual Physical Activity on Bone & Metabolic Health in Pediatric Cancer Survivors
Recruiting NCT05909878 - Virtual Reality Distraction for Anxiety (VR-IMAGINE at HSJ) N/A